These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 35298959

  • 1. Phase Ib/II study of ceritinib in combination with ribociclib in patients with ALK-rearranged non-small cell lung cancer.
    Santoro A, Su WC, Navarro A, Simonelli M, Ch Yang J, Ardizzoni A, Barlesi F, Hyoung Kang J, DiDominick S, Abdelhady A, Chen X, Stammberger U, Felip E.
    Lung Cancer; 2022 Apr; 166():170-177. PubMed ID: 35298959
    [Abstract] [Full Text] [Related]

  • 2. Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
    Nishio M, Murakami H, Horiike A, Takahashi T, Hirai F, Suenaga N, Tajima T, Tokushige K, Ishii M, Boral A, Robson M, Seto T.
    J Thorac Oncol; 2015 Jul; 10(7):1058-66. PubMed ID: 26020125
    [Abstract] [Full Text] [Related]

  • 3. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.
    Kim DW, Mehra R, Tan DSW, Felip E, Chow LQM, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Sutradhar S, Li S, Szczudlo T, Yovine A, Shaw AT.
    Lancet Oncol; 2016 Apr; 17(4):452-463. PubMed ID: 26973324
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
    Califano R, Greystoke A, Lal R, Thompson J, Popat S.
    Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
    Hida T, Seto T, Horinouchi H, Maemondo M, Takeda M, Hotta K, Hirai F, Kim YH, Matsumoto S, Ito M, Ayukawa K, Tokushige K, Yonemura M, Mitsudomi T, Nishio M.
    Cancer Sci; 2018 Sep; 109(9):2863-2872. PubMed ID: 29959809
    [Abstract] [Full Text] [Related]

  • 14. Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6.
    Wu YL, Shi Y, Tan DSW, Xiaoqing L, Cheng Y, Zhou J, An TT, Lu Y, Zhu B, Bai C, Passos VQ, Lau YY, Xun L, Zhang L.
    Lung Cancer; 2020 Dec; 150():240-246. PubMed ID: 33249379
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF.
    Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.